Canaccord raised the firm’s price target on Evolent Health (EVH) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model following mixed Q1 results and where the company showed they continue to win new business.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH: